Atossa Therapeutics, Inc. - Common Stock (NQ:ATOS)

2.280 -0.090 (-3.79%)

Delayed Quote Updated: 2:04 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atossa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 08, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023 ↗

September 08, 2023

Via Benzinga

Atossa Therapeutics backing Endoxifen in the fight against breast cancer

August 23, 2023

--News Direct--

Via News Direct

Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer? ↗

August 09, 2023

Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the...

Via Benzinga

Recap: Atossa Therapeutics Q2 Earnings ↗

August 08, 2022

Atossa Therapeutics (NASDAQ:ATOS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:30 PM. Here's what investors need to know about the announcement.

Via Benzinga

50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis

July 12, 2023

Via ACCESSWIRE

50% Of Women Have Elevated Breast Density, Which Significantly Decreases The Effectiveness Of Mammography – Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis ↗

July 11, 2023

One in eight women will be diagnosed with breast cancer during

Via Benzinga

3 Penny Stocks to Make Your ‘Get Rich’ Dreams Come True ↗

July 06, 2023

When it comes to potentially profitable penny stocks, some can create unimaginable fortunes for patient investors. Others, not so much.

Via InvestorPlace

3 Penny Stocks Set to Pass the $5 Mark Soon ↗

June 23, 2023

Here are three high potential penny stocks with recent news that could move them above the $5 mark in the next six to 12 months

Via InvestorPlace

3 Penny Stocks That Could Skyrocket in the Next 12 Months ↗

June 07, 2023

Find the top penny stocks to buy, and you can make a fortune. Pick the wrong one and there are also plenty of horrors.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

May 24, 2023

It's time for a dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday morning!

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

May 17, 2023

We're starting off Wednesday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning!

Via InvestorPlace

7 High-Potential Penny Stocks in the Biotech Sector ↗

May 04, 2023

Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider.

Via InvestorPlace

3 Best Penny Stocks Under $1 to Buy in April ↗

April 11, 2023

By their very nature, the best penny stocks under $1 are a huge gamble with potentially huge returns for speculative investors.

Via InvestorPlace

The 3 Best Biotech Stocks Under $1 to Buy for April ↗

April 04, 2023

While risky, here are some of the best biotech stocks under $1, with solid catalysts, investors may want to consider.

Via InvestorPlace

The 3 Best Biotech Stocks Under $1 to Buy for January ↗

January 26, 2023

Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Monday ↗

December 05, 2022

During Monday's session, 49 companies made new 52-week lows.

Via Benzinga

Why Is NuZee Down By Over 21%: Here Are 38 Stocks Moving Premarket ↗

August 08, 2022

Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares rose 46% to $6.98 in pre-market trading after jumping around 46% on Friday. The company recently said it expects unaudited...

Via Benzinga

20 Stocks Moving in Wednesday's Pre-Market Session ↗

June 08, 2022

Gainers Cyren Ltd. (NASDAQ: CYRN) rose 31.1% to $2.32 in pre-market trading after the company entered into an agreement with Content Services Group to sell all equity interests in its legacy secure...

Via Benzinga

61 Biggest Movers From Yesterday ↗

April 28, 2022

Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

January 07, 2022

Gainers ContraFect (NASDAQ:CFRX) stock mo...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 06, 2022

Gainers ContraFect (NASDAQ:CFRX) stock in...

Via Benzinga

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 20, 2021

Gainers Tenet Healthcare (NYSE:THC) stock r...

Via Benzinga

ATOS Stock Holders Should Mark Their Calendars for Oct. 7 ↗

September 10, 2021

Today, investors in Atossa Pharmaceuticals and ATOS stock appear to be cheering a delayed shareholder vote on a stock issuance proposal.

Via InvestorPlace

Atossa To Conduct Endoxifen Mid-Stage Study In Sweden ↗

September 02, 2021

Atossa Therapeutics Inc (NASDAQ: ATOS) has received approval from the Swedish Ethics Review Authority to begin a Phase 2 clinical study of oral Endoxifen to reduce...

Via Benzinga

Atossa Therapeutics Stock Lost Its Covid Mojo, and Its Pipeline Fails To Impress ↗

August 31, 2021

Atossa’s Covid treatment is too little too late and I am concerned about the market size for Endoxiden. Avoid ATOS stock here.

Via InvestorPlace

Atossa Therapeutics Has a Steep Climb Ahead of It ↗

August 31, 2021

Atossa Therapeutics is popular with the Reddit crowd. However, ATOS stock doesn’t make the top 25 on the platform. Should you buy it anyway?

Via InvestorPlace

As its Meme Status Has Come and Gone, Skip Out on Atossa Therapeutics Stock ↗

August 30, 2021

No matter talked about by the Reddit set, despite its heavy short-interest, ATOS stock will likely fall lower rather than get squeezed

Via InvestorPlace

Atossa Therapeutics May Look Tempting, but There’s No Reason to Get in Now ↗

August 30, 2021

ATOS stock has some exciting points, but its story sends a message investors have heard, namely the price of progress is dilution.

Via InvestorPlace

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.